14, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug ... agreed to sell an aggregate of 15,312,500 shares of its common stock and warrants to purchase up to …
Generex Biotechnology Company (NASDAQ: GNBT), a drugdelivery system and technology developer, has filed an offering by sellingstockholders of up to 74,475,861 shares of common stock. The proposed maximum aggregateoffering price is …
Generex Biotechnology Corporation (OTCPink:GNBT) today announced that it has achieved the elimination ... outstanding and convertible into 33,939,394 shares of Generex common stock (based on the VWAP as at that date). There were …
Generex Biotechnology Corporation (GNBT) today announced a reverse stock split of its shares of common stock at a ratio of 1-for-1000. As of the open of the market on March 14, 2017, the Company’s common stock will begin trading on a …
Generex Biotechnology (GNBT) just announced a few minutes ago that results from ... Generex Biotechnology has since broken out of its narrow trading range and is now up 0.11 at $0.43. The stock is attempting to rebound from the lows of …
Shares of Generex Biotechnology (PINK:GNBT) have lost a whopping 74% so far this year, sending shares to a 52-week low of under 4 cents. The company shed nearly 10% in one day late last month after announcing a secondary stock
Generex Biotechnology Corporation (GNBT) is pleased to announce that on January 19 ... equity securities in the …
GNBT, (+16.6%) Issues white paper outlining the advantages of its Ii-Key technology in the development of an effective …
Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution By MD Becker Partners Sep 19, 2011 9:30 am Often overlooked, ...